Introduction
Thyroid tumors represent 1% of all neoplasms [1, 2] , and differentiated thyroid tumors (papillary and follicular) account for 80%-85% of all thyroid tumors [3, 4] . Most cases of differentiated thyroid tumor have a favorable outcome.
Anaplastic thyroid carcinoma (ATC) accounts for 5%-15% of primary malignant thyroid neoplasms [5] . The pronounced differences in the biologic behavior of the various histologic types of thyroid carcinoma are well known. In contrast to papillary and follicular thyroid carcinoma, ATC is one of the most aggressive neoplasms in humans [6] . Generally, it is rapidly fatal, with a mean survival of 6 months after diagnosis [7] . Because ATC is rare, it has been difficult to study a sufficient number of patients to obtain a better understanding of the natural history of the tumor and the factors that may influence treatment and survival.
ATC usually does not concentrate iodine or express thyroglobulin. It is essential to verify the diagnosis histologically because insular thyroid cancer, lymphomas, and medullary thyroid cancer are occasionally confused with undifferentiated neoplasms [8, 9] . Immunohisto- ' The US Government's right to retain a non-exclusive, royalty-free licence in and to any copyright is acknowledged. chemical study with antikeratin antibodies is helpful in establishing the diagnosis.
Incidence and etiologic factors
The incidence of ATC is approximately one or two cases/million annually, but this varies geographically, with a higher incidence in Europe than in the US [10] . Also, a higher incidence has been reported in areas with endemic goiter [11, 12] . Most of these tumors grow on a preexisting thyroid nodular goiter or on a preexisting differentiated thyroid carcinoma, especially a follicular thyroid tumor [13] [14] [15] [16] .
Molecular biology studies have shown that ATC is associated with a p53 gene mutation (Figure 1 ) [17] [18] [19] . The p53 gene controls cellular proliferation through a suppressive effect on cell growth, and the inactivation of this control by the mutation may result in the anaplastic transformation of the differentiated thyroid carcinoma (Figure 1 ).
Another hypothesis is that transforming growth factor B (TGFB) type II receptors (TBRII) are expressed less in ATC. TGFB is a physiologic regulator of thyroid epithelial cell growth and differentiation, and the reduced expression of TBRII mRNA in thyroid carcinoma is correlated directly with the aggressiveness of the tumor [20] . Another protein that may be implicated in dedifferentiation of thyroid cancer is CD97 [21] , which has been reported in high concentrations in 11 cases of undifferentiated thyroid neoplasms and has been suggested as a marker of dedifferentiation [21] . Mutations in (3-catenin, a ubiquitous cytoplasmatic protein, is common in ATC and could activate the transcription. These findings support the idea that (3-catenin acts as an oncogene and contributes to the aggressive behavior of this tumor [22] . A possible genetic explanation for the transformation from a well-differentiated cancer to ATC is suggested by the loss of 16p, which has been observed in 62.5% of ATC cell lines. Thus, a gene in 16p may be closely associated with the transformation [23] . Moreover, it has been found that ATC produces large amounts of different types of cytokines (interleukin-8 and -6 [24] ) and growth factors (granulocyte colony-stimulating factor [25, 26] , and granulocyte-macrophage colonystimulating factor [27] ).
Pathology
The diagnosis of ATC is often based on clinical onset. ATC is frequently seen as a large and firm thyroid mass infiltrating extrathyroidal tissues. Macroscopically, the tumor may replace most of the thyroid gland and invade the surrounding structures. The cut surfaces often present foci of hemorrhage and necrosis [14] . Microscopically, ATC shows considerable variation. It has three distinct morphologic patterns: squamoid, spindle cell, and giant cell [13, 28] . The squamoid pattern is characterized by the formation of distinct nests of irregular configuration; pleomorphism is moderate, and the cytoplasm is abundant. The spindle cells occasionally are arranged in fascicles, resembling a sarcoma; at other times, the degree of nuclear pleomorphism and scattered multinucleated giant tumor cells resemble the form of a fibrous histiocytoma. The giant cell pattern is characterized by a higher degree of pleomorphism than that of the other patterns, with numerous tumor giant cells. All three patterns have high mitotic activity, large foci of necrosis, and a marked degree of invasiveness ( Figure 2 ). The tumors invade adipose tissue and skeletal muscle and sometimes ulcerate the skin. Although the recognition of these different patterns has diagnostic importance, the patterns do not appear to have different biologic behaviors. Thus, clinically, ATC is considered as a single group of tumors. The coexistence of a well-differentiated carcinoma and ATC has been reported [28] [29] [30] [31] , and it also has been suggested that the anaplastic transformation may be induced by the administration of radioactive iodine [16, 32, 33] .
Currently, pathologic evaluation suggests that small cell ATC does not represent any subset of ATC, but a form of lymphoma [34, 35] .
The cytologic pattern obtained by fine-needle aspiration is based on the following features: giant or spindle cells that are isolated or form sheets or small clusters; multilobulated single or multiple nuclei; irregular chromatin clumps, hyperchromasia, or granular chromatin; multiple irregularly shaped micro-and macronucleoli; variable amounts of cytoplasm; and necrosis ( Figure 3 ) [36] .
Immunocytochemical study can help differentiate ATC from other neoplasms with which it can be confused * * ; (sarcomas, lymphomas) [28, 37, 38] . Keratin reactivity is present in 40%-100% of the tumors and vimentin and keratin may be coexpressed [37] [38] [39] [40] . Carcinoembryonic antigen (CEA) positivity has been reported in some of the more squamoid ATC [28, 37] . The reactivity for keratin, epithelial membrane antigen (EMA), and CEA confirms the epithelial nature of the neoplasm. ATC is usually negative for thyroglobuhn. Also, the results of immunostaining for thyroglobuhn indicate that it is of little or no value in the diagnosis of ATC [41] [42] [43] .
Clinical onset
ATC occurs mainly in the elderly. The median age of 84 consecutive patients evaluated at the Mayo Clinic from 1971 to 1993 was 70 years (range 43-87 years) (Giufridda D et al., unpublished data). Females were affected more frequently than males (F:M = 1.3:1; 57% vs. 43%). Advanced ATC has typical clinical manifestations. The most common is a rapidly enlarging thyroid mass. Hemorrhage into the thyroid mass may be manifested as rapid enlargement and accompanied by pain and severe dysphagia or hoarseness (Figure 4) . The most frequent and important signs and symptoms of the patients in the Mayo Clinic series are listed in Table 1 . The most common symptom was hoarseness (77%), followed by dysphagia (56%), vocal cord paralysis (49%), cervical pain (29%), and dyspnea (19%). In the same series, the following features were found on initial examination: single nodule (58%), multiple nodules (36%), bilateral involvement (24%), and a hard and fixed lesion (75%). The tumor was larger than 10 cm in 6% of the patients and was from 5 to 10 cm in 58%. Also, surrounding structures were invaded in 70% of the patients: muscles (65%), trachea (46%), esophagus (44%), laryngeal nerve (27%), and larynx (13%). Lymph node metastases were observed in 43% of the patients.
Distant metastases are observed in 20%-50% of cases at the time of diagnosis. The most frequent site of Figure 4 . Examination of a 53-year-old woman with a rapidly growing thyroid mass, shortness of breath, and dysphagia revealed a large rubbery goiter, 13 x 10 x 6 cm. Fine-needle aspiration biopsy showed anaplastic cancer. External radiotherapy was initiated but the patient died one month after diagnosis. distant metastasis is the lung, followed by bone, skin, and brain [35] . Cardiac [27] and intra-abdominal metastases have also been described [44] . In the Mayo Clinic series, lung metastases were diagnosed in 45% of the patients and bone metastases in 12% at the time of diagnosis.
Accurate staging with laryngoscopy, neck ultrasonography, bone scan, and computed tomograpy (CT) of head, neck, mediastinum, thorax, and abdomen [45] is important for determining the extent of infiltration by the tumor.
Clinical course and prognosis
ATC is a rapidly growing neoplasm and one of the most aggressive tumors in humans [6] . The prognosis is extremely poor. The mean overall survival is about six months [15, 35] . The most important prognostic factors are age and extent of disease at presentation. Usually, patients younger than 60 years have less extensive disease at the time of diagnosis. In a series of patients evaluated at Mayo Clinic from 1946 to 1971, Cox multiple regression Abbreviations: C -chemotherapy; R -radiotherapy; S -surgery.
indicated that the following were potential predictors of poor survival: histologic type of cell (giant cell carcinoma), size of lesion (6 cm or larger), surgical treatment (biopsy only), invasion of adjacent structures, and extent of disease (distant metastases) [46] . Also, the anaplastic component needs to be assessed to determine whether it is a small or predominant component [28, 47] .
Treatment
Treatment of ATC has not been standardized (Table 2) . Most patients die within a few months after diagnosis, primarily of strangulation caused by local tumor invasion. Although cure is rare, every effort should be made to control the disease locally to improve the patient's quality of life. Surgery, radiotherapy, or chemotherapy alone is seldom adequate for controlling the disease, but a combination of these treatments may improve local control [30, 46, 48, 49] .
Surgery
An ATC usually cannot be resected completely because it is very invasive. Thus, surgical treatment is indicated primarily for relief of airway obstruction. Total thyroidectomy and radical neck dissection may have no advantage over a less aggressive surgical approach [50, 51] . However, total thyroidectomy can be justified if cervical and mediastinal disease can be resected. Otherwise, debulking of the tumor can be considered adequate treatment. It also is adequate for a histologic examination. A more complete thyroid resection is associated with longer survival than biopsy alone [52, 53] . Local control of disease is an important component of clinical management [54] .
Radiotherapy
External beam radiography has been helpful in delaying local recurrence and in preventing thoracic outlet obstruction [55] . It has not been shown to alter the mortality rate but only the local control of the disease. External beam radiotherapy can provide substantial benefit in local control of disease, although ATC is considered a radioresistant tumor. Simpson [55] first reported treating ATC with a small number of large radiation fractions (350-800 cGY). This protocol failed to eradicate local disease, and all patients died within nine months after diagnosis. Hyperfractionated local radiotherapy seems to be more effective than conventional treatment, but toxicity is higher. Wong et al. [56] subsequently treated 14 patients with hyperfractionation (100 cGy four times daily) and achieved complete tumor regression in 43% and partial regression in 50%. However, after three treatment-related deaths, the protocol was discontinued.
Junor et al. [52] reported on 91 patients who had radiotherapy after surgery and noted that patients who had total or partial thyroidectomy had significantly better survival than those who had biopsy only. Most of the patients received between 30 and 60 Gy given in 2 Gy fractions (median survival, 21 weeks; 6-month survival, 45%; and 9-month survival, 32%). Levendag et al. [54] reported on 51 patients who received external beam radiotherapy and surgery and concluded that local control is indispensable for achieving better short-term survival. Patients with distant metastases but locally free of disease had a median survival of 7.5 months compared with 1.6 months for those with residual local disease. In the study of Demeter et al. [57] , 12 patients received radiotherapy and 42% had a documented response. Mitchell et al. [58] reported that 10 of 17 patients who received high-dose accelerated radiotherapy had a partial or complete response; however, the toxicity was unacceptable.
Radiotherapy and chemotherapy
Wong et al. [56] treated ATC with radiotherapy in combination with doxorubicin (40 mg/m 2 ) as a radiosensitizing agent, but the results were disappointing, with a median survival less than six months and unacceptable toxicity. Radiotherapy in conjunction with a chemotherapeutic agent as a radiosensitizer has been attempted by others. Kim and Leeper [59, 60] treated 19 patients with hyperfractionated radiation (160 cGy per treatment twice daily for 3 days per week, to a total dose of 5,760 cGy in 40 days) and weekly doxorubicin (10 mg/m 2 , 1.5 hours before radiotherapy) and 84% had complete remission and 16% had local control of the disease. The median survival was 12 months. Tennvall et al. [61, 62] gave a combination of radiotherapy and chemotherapy preoperatively and postoperatively after attempted surgical resection of local disease. Two regimens of hyperfractionated radiotherapy were used: preoperative radiotherapy was given to a total dose of 30 Gy and an additional 16 Gy was given postoperatively. The daily fraction was 1.0 or 1.3 Gy x 2, five days a week. Doxorubicin, 20 mg, was administered one to two hours before the first radiotherapy each week. Debulking surgery was possible in 23 of the 33 (70%) patients. No sign of local recurrence was detected in 48% of patients, and 24% of patients died of local failure. Overall survival was similar for the 1.0 and 1.3 Gy regimens, with a median of 3.5 and 4.5 months, respectively. Four (12%) patients survived longer than two years.
Chemotherapy
Despite various approaches with single agents and various combinations of doxorubicin, etoposide, cisplatin, bleomycin, and vincristine, chemotherapy has not provided adequate control of ATC, and there is no consensus about which chemotherapeutic agents should be used. In vitro chemosensitivity testing has been proposed to avoid ineffective chemotherapy [63] . Doxorubicin has been used most commonly, but the results have been disappointing. According to Pacini et al. [64] , of nine patients with undifferentiated thyroid carcinoma who received doxorubicin monotherapy, eight had progression of disease. In a randomized controlled study (Eastern Cooperative Oncology Group), Shimaoka et al. [65] observed only 1 response among 21 patients treated with doxorubicin (60 mg/m 2 ) monotherapy. However, the results of combination chemotherapy with doxorubicin (60 mg/m 2 ) and cisplatin (40 mg/m 2 ) were encouraging, and 6 of 18 patients had a response. This study showed that the response achieved with a combination of drugs is superior to that of single-agent chemotherapy.
In a review of the literature on the treatment of ATC, Ahuja and Ernst [66] reported that the response rate with doxorubicin monotherapy was 22.1% (17 of 77 patients). De Besi et al. [67] reported that of five patients who received chemotherapy with a combination of bleomycin, doxorubicin, and cisplatin, three had a response.
In a pilot study by the Japanese Society of Thyroid Surgery [68] , 15 patients with ATC received cisplatin (40 mg/m 2 ), doxorubicin (60 mg/m 2 ), etoposide (100 mg/m 2 x 3 days), peplomycin (5 mg), and granulocyte colonystimulating factor (to prevent bone marrow depression) and 11 died of disease within 7 months after treatment and 4 survived from 3 to 11 months. In the study of Auersperg et al. [69] , 89 patients with ATC received vinblastine, cisplatin, doxorubicin, and mitoxantrone as primary treatment preoperatively, and 15% died before surgery. Of the patients who completed the treatment, only 9% survived longer than one year. Biganzoli et al. [70] treated patients with a combination of carboplatin and epirubicin to reduce the nephrotoxicity of cisplatin; the medial survival was two months. Demeter et al. [57] reported a response rate of 55% with postoperative chemotherapy.
Multimodality treatment
ATC is highly malignant and survival is not affected by either radiotherapy or chemotherapy alone. In fact, the tumor often grows during treatment. The cause of death for most patients is local tumor invasion. A combination of surgery, chemotherapy, and radiotherapy [69, 71, 72] has been effective in some patients, both for survival and local disease control, and has prevented strangulation due to tumor invasion of the trachea [48, 71] . In the report of Venkatesh et al. [39] , 11% of patients receiving both radiotherapy and chemotherapy survived for an average of 13 months. Tallroth et al. [72] divided 47 patients into 4 treatment groups. The first group received methotrexate and radiotherapy (30-40 Gy) and had a median overall survival of 9 months. The second group received bleomycin, cyclophosphamide, and fluorouracil and radiotherapy and had a median survival of four months. The third group received the same therapy as the second group with the addition of surgical resection; the median survival was also four months. The fourth group received doxorubicin, radiotherapy, and surgical resection and also had a median survival of four months. Of the 34 patients treated with bleomycin, cyclophosphamide, and fluorouracil and radiotherapy, only 11 died of local growth. Werner et al. [73] had similar results with a combination of chemotherapy and external beam radiotherapy. Most patients with anaplastic giant cell thyroid carcinoma should no longer die of strangulation caused by local tumor growth.
Mancusi et al. [74] compared, without regard to the type of surgery, the effects of chemotherapy plus radiotherapy with those of chemotherapy or radiotherapy alone. Survival was significantly better with the combination treatment.
Schlumberger et al. [75] used two different prospective protocols to treat 20 patients. Patients younger than 65 years received a combination of doxorubicin (60 mg/m 2 ) and cisplatin (90 mg/m 2 ), and those older received mitoxantrone (14 mg/m 2 ). Radiotherapy (17.5 Gy in seven fractions to the neck and the superior mediastinum) was administered between days 10 and 20 of the first four cycles of chemotherapy. Three patients survived longer than twenty months, and five patients had a complete response. No response was seen in patients with distant metastases. The treatment was effective for survival and local control, preventing death from local invasion. After making the diagnosis of ATC with fineneedle biopsy or open biopsy, Tezelman and Clark [49] administered bleomycin one to two hours before each dose of radiotherapy and fluorouracil before every second treatment. Three weeks after this combination therapy, thyroidectomy was performed to remove as much tumor as possible, and then two to three weeks later, radiotherapy and chemotherapy were again administered. This method of treatment prevented recurrence of tumor in the neck, and no patient died of strangulation. Patient care requires close attention to pain control, maintenance of the airway, and other quality-of-life issues.
Variable results have been reported with several chemotherapeutic agents, including paclitaxel, fluorouracil, and hydroxyurea plus radiotherapy [76] . Paclitaxel was added to fluorouracil and hydroxyurea because of its activity in head and neck cancer and its ability to enhance the efficacy of radiation. Preclinical studies have shown a beneficial effect of paclitaxel on human anaplastic cell lines [77] .
Conclusions
Aggressive multimodality treatment regimens show promise in improving local control in patients with ATC. Survival rates for patients with anaplastic carcinoma of the thyroid, however, remain low. Despite intense application of such complicated therapy, no standardized successful treatment protocol has yet been established.
